⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Centessa Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Centessa Pharmaceuticals
↗Altrincham, United Kingdom
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of orexin receptor 2 (OX2R) agonists. The company utilizes a structure-based drug design approach to target the orexin pathway, aiming to treat sleep-wake disorders such as narcolepsy (Type 1 and 2) and idiopathic hypersomnia, as well as broader neurological and neuropsychiatric conditions.
CLASSIFICATION
SIZE & FINANCIALS
Employees:101-250
Founded:2021
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Post-IPO
Investors:Medicxi, General Atlantic
STOCK
Exchange:NASDAQ
Ticker:CNTA
Market Cap:$6.15B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2a
Modalities:Small molecule
Active Trials:0
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Eli Lilly and Company
Acquired By:Eli Lilly and Company (2026-03-01)
Key Partnerships:Eli Lilly (Acquirer)
COMPETITION
Position:Emerging
Competitors:Takeda, Eisai
LEADERSHIP
Key Executives:
Mario Alberto Accardi - CEO
Board Members:Francesco De Rubertis, Mario Alberto Accardi, Mary Lynne Hedley, Samarth Kulkarni
LINKS
Website:centessa.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Centessa Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.